Candidate drugs targeting the inflammatory IL-1β, TNFα and IL-6 triad18,23 and/or promoting antioxidant responses show promise for ameliorating hemorrhagic cystitis but have not progressed beyond preclinical testing. Here, IL6 is linked to hemorrhagic cystitis.